Skip to content
TrialScanner

NCT02215629

Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia

Phase 1WithdrawnVSTMLead

Registry record

Lead sponsor
Verastem, Inc.
Conditions
Relapsed or Refractory Acute Myeloid Leukemia; Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Primary completion
Sep 2016Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT02215629 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02215629: Dose Escalation Study in... | TrialScanner